Navigation Links
inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
Date:2/28/2008

rter of 2007, compared to $18.5 million for the fourth

quarter of 2006.

-- Adjusted income from continuing operations increased 35% to $15.3

million for the fourth quarter of 2007, compared to $11.3 million for

the fourth quarter of 2006. GAAP income from continuing operations

increased 72% to $15.5 million for the fourth quarter of 2007, compared

to $9.0 million for the fourth quarter of 2006.

-- Adjusted diluted earnings per share (EPS), including stock compensation

expense, increased 27% to $0.47 for the fourth quarter of 2007,

compared to $0.37 for the fourth quarter of 2006. GAAP diluted EPS

increased 62% to $0.47 for the fourth quarter of 2007, compared to

$0.29 for the fourth quarter of 2006.

Full Year 2007 Results from Continuing Operations:

-- Total revenues increased 28% to $977.3 million for 2007, compared to

$766.2 million for 2006. Net revenues increased 26% to $796.7 million,

compared to $631.6 million for 2006. Pro-forma organic net revenue

growth for 2007 was 13% compared to the same period last year.

-- Adjusted operating income increased 25% to $102.2 million for 2007,

compared to $81.6 million for 2006. GAAP operating income increased

21% to $94.8 million for 2007, compared to $78.1 million for 2006.

-- Adjusted income from continuing operations increased 25% to $51.3

million for 2007, compared to $41.0 million for 2006. GAAP income from

continuing operations decreased 4% to $47.2 million for 2007, compared

to $49.2 million for 2006. This decrease is reflective of the $1.0

million and $9.1 million of tax benefits recognized in 2007 and 2006,

respectively, as described in note (1).

-- Adjusted diluted EPS, including stock compensation expense, increased

16% to $1.59 for 2007, compared to $1.37 for 2006. GAAP diluted EPS'/>"/>

SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
2. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
3. inVentiv Health Provides Updated Information on December 11th Investor Day
4. inVentiv Health Creates Client Development and Integration Team
5. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
6. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
7. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
8. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
9. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
10. Former Blue Cross/Blue Shield Account Manager Sentenced for Health Care Fraud Scheme, Tax Evasion
11. UCLA launches network to study health care disparities affecting minorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...nced today the publication of Reproductive Health...trimester abortion: women,s health and public poli...ues regarding methods, values, stigma, the burden ... complicated reality of women,s lives and decision...ew out of a conference on second trimester abortio...
(Date:12/2/2008)...ember 1, 2008, issue of Clinical Cancer Research ... Research, show lapatinib benefits women with HER2...ative breast cancer or those who express EGRF alon...sclassification of metastatic breast cancer patien...rom receiving optimal therapy. , Lapatinib, an ...
(Date:12/2/2008)...008) The complexity of vital organ systems makes...ue culture methods for specific cell types allow r...ent parts that can be readily manipulated and obse...rotocols ( www.cshprotocols.org/TOCs/toc12_08.dtl...lture methods for cells from the immune system and...
(Date:12/2/2008)... Stroller Strides , the country,s largest and f...heir babies, has announced that Pampers , a le...ed on as the company,s premier sponsor for 2009. ,...companies, shared mission of caring for babies, to...ve Pampers as our premier sponsor," said Lisa Drux...
Breaking Medicine News(10 mins):Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:HER2 levels may aid in treatment selection for metastatic breast cancer 2Health News:Cold Spring Harbor Protocols features tissue culture methods for immune cells and neurons 2Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2
Tony Clement Canadian Health minister released the revised version of the Canada Food Guide. The new guide described as a manual on healthy lifestyle choices does exactly that, according to the healt
..., there is a pronounced increase of mental illness...Syndrome, autism spectrum disorders, obsessive// c...is study was published in the Archives of Pediatri...re not sure if this ascend could be attributed to ...
...d when his doctor discovered a potentially life-th...lood vessel, the aorta, during a routine// physica...elieved to find out that the weak spot, called an ... it was still small. For the next few years, a va...
...aunched production of unusual beer from cow's milk...g for ways to put his milk surpluses to good use./...n the store shelves Thursday, in the Japanese city...ountry's northernmost island of Hokkaido. The pr...
Other Medicine News:Health News:‘Manual on Healthy Lifestyle Choices’ Releas 2Health News:Early Detection of Artery Weakening Can Be a Life-Saver 2Health News:Early Detection of Artery Weakening Can Be a Life-Saver 3
(Date:12/2/2008)...LA, Calif., Dec. 2 TorreyPines The...positive results from a 26 patient Phase II trial ...r xerostomia, or dry mouth, in patients with Sjogr... a statistically significant increase in salivary ...oses: 10 mg, 15 mg, and 20 mg. These doses were sa...
(Date:12/2/2008)..., Ill., Dec. 2 Horizon Therapeutic...ny, today announced that two pivotal,Phase 3 tria...didate, HZT-501,met all primary endpoints. HZT-5...roduct containing ibuprofen and famotidine, demons...he incidence of non-steroidal,anti-inflammatory d...
(Date:12/2/2008)...DA, Md., Dec. 2 Micromet...any developing novel, proprietary antibodies for t...e diseases, today announced that it has entered in...ancing Facility (CEFF) with Kingsbridge Capital Li...s of the agreement, Kingsbridge has committed to p...
(Date:12/1/2008)...O, Dec. 2 New research ...t-slice computed tomography (CT) scanner in an eme...of stroke victims who receive a potentially life-s...t North Shore Medical Center (NSMC)-Salem Hospital...nnual meeting of the Radiological Society of North...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 1OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 2OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 3New technique produces genetically identical stem cells 6347 1New technique produces genetically identical stem cells 6347 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 1Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 3Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 4Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 5Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 1Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 2Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 3
...ta to be Presented April 15th at EASL Conference i...pril 11, 2007,/PRNewswire-FirstCall/ - MIGENIX Inc...ious diseases, has received new top-line results,c...s (November 6,2006) indicating evidence of clinic...study using the oral alpha-glucosidase,inhibitor, ...
...MBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gl...d biopharmaceutical,company, announced today that ...omidepsin will be presented at the 2007,Annual Mee...h,taking place in Los Angeles, CA April 14-18, 200...preclinical research,performed by multiple academi...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: